{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:01:52Z","timestamp":1780462912100,"version":"3.54.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008392","name":"Sundhed og Sygdom, Det Frie Forskningsr\u00e5d","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R2-A198-09-S2"],"award-info":[{"award-number":["R2-A198-09-S2"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.leukres.2011.01.025","type":"journal-article","created":{"date-parts":[[2011,2,17]],"date-time":"2011-02-17T06:35:50Z","timestamp":1297924550000},"page":"e84-e86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Is hepatotoxicity in patients treated with gemtuzumabozogamicin due to specific targeting of hepatocytes?"],"prefix":"10.1016","volume":"35","author":[{"given":"Maciej Bogdan","family":"Maniecki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Hasle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knud","family":"Bendix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger Jon","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.leukres.2011.01.025_bib0005","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/00001813-200208000-00002","article-title":"Gemtuzumab Ozogamicin (CMA-676, Mylotarg) for the treatment of CD33+ acute myeloid leukemia","volume":"13","author":"Voutsadakis","year":"2002","journal-title":"Anticancer Drugs"},{"issue":"5","key":"10.1016\/j.leukres.2011.01.025_bib0010","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1517\/14712598.1.5.893","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse","volume":"1","author":"Sievers","year":"2001","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"10.1016\/j.leukres.2011.01.025_bib0015","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/00001622-200111000-00016","article-title":"Mylotarg: antibody-targeted chemotherapy comes of age","volume":"13","author":"Sievers","year":"2001","journal-title":"Curr Opin Oncol"},{"issue":"6","key":"10.1016\/j.leukres.2011.01.025_bib0020","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.leukres.2011.01.025_bib0025","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2004-10-3821","article-title":"Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia","volume":"106","author":"Arceci","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.01.025_bib0030","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial","author":"Burnett","year":"2010","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.leukres.2011.01.025_bib0035","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2009-10-246470","article-title":"Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study","volume":"115","author":"Lowenberg","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2011.01.025_bib0040","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.leukres.2006.07.005","article-title":"Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project","volume":"31","author":"McKoy","year":"2007","journal-title":"Leuk Res"},{"issue":"7","key":"10.1016\/j.leukres.2011.01.025_bib0045","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/cncr.21326","article-title":"Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence","volume":"104","author":"Larson","year":"2005","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.leukres.2011.01.025_bib0050","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1182\/blood-2007-09-114165","article-title":"Impaired CD163-mediated hemoglobin-scavenging and severe toxic symptoms in patients treated with gemtuzumab ozogamicin","volume":"112","author":"Maniecki","year":"2008","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261100035X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261100035X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:57:24Z","timestamp":1758934644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261100035X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S014521261100035X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2011.01.025","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is hepatotoxicity in patients treated with gemtuzumabozogamicin due to specific targeting of hepatocytes?","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2011.01.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}